Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05708859
Other study ID # 22915-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 2, 2024
Est. completion date May 2026

Study information

Verified date October 2023
Source Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Contact Sajad Hamal, MS
Phone 13109749336
Email shamal@lundquist.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.


Description:

This is a multi-center study in which 120 male and female participants who meet the eligibility criteria will be randomized. Study will assess changes in coronary atheroma volume comparing tirzepatide 15 mg/week plus Standard of Care (SOC), as compared to placebo plus SOC. Potential eligible participants may be prescreened for eligibility prior to the screening visit and must have a diagnosis of atherosclerosis (as assessed by >10% atheroma on CCTA) and T2DM. Patients must be on a stable medical regiment (>4 weeks on statin therapy and diabetes medications) and undergo screening CCTA to demonstrate coronary plaque. Participant eligibility will be assessed by the Imaging Core Lab. If the participant meets all entry criteria during baseline visit, then consenting participants will be randomized 1:1 to receive tirzepatide on top of standard of care for treatment period of 12 months. Participants will be asked to maintain stable doses of statins and diabetes medications. Persistent hyperglycemia will be treated by primary physician or endocrinologist,


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date May 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female 40 years to 80 years of age at signing of informed consent 2. Type 2 DM of minimum 5 years duration with HbA1c =7.0% to =10.5% 3. Body mass index (BMI) =25 kilograms per meter squared (kg/m²) 4. Presence of two discrete coronary artery plaques with visual diameter stenosis >20% on CCTA 5. At the baseline visit, participants must be on a stable (>4 weeks) regiment of diabetes medications. 6. Patients using oral hormonal contraceptives must switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation Exclusion Criteria: 1. Have had a major cardiovascular event within the last 60 days 2. Have type 1 diabetes mellitus 3. Current use of GLP1-RA 4. Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months 5. Are currently planning treatment for diabetic retinopathy and/or macular edema 6. Have history of, or currently planning a coronary, carotid, or peripheral artery revascularization (ie - stent, bypass) 7. Have a history of pancreatitis 8. Have a history of ketoacidosis or hyperosmolar state/coma 9. Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery 10. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years 11. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) 12. Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement 13. Planned or Prior Bypass surgery 14. Contradiction for CCTA (e.g. serious allergic reaction to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA visit as assessed by the imaging core lab. 15. Uncontrolled severe hypertension: systolic blood pressure > 180 mmHg or diastolic BP > 100 mm Hg prior to randomization (assessed at the screening visit) despite antihypertensive therapy 16. Heart Failure NYHA Class III or IV at the screening visit 17. Renal insufficiency (eGFR <40 ml/min/1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the screening visit. 18. Hospitalization for major cardiovascular event including heart failure in the past 2 months

Study Design


Intervention

Drug:
Tirzepatide
Tirzepatide 15mg Subcutaneous Solution
Placebo
Volume matched Subcutaneous Solution

Locations

Country Name City State
United States Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) Torrance California

Sponsors (2)

Lead Sponsor Collaborator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction of total non-calcified coronary plaque volume Reduction of total non-calcified coronary plaque volume from baseline (start of the study) till the final visit will be measured using Coronary Computed Tomography Angiography (CCTA). 12 months
Secondary Reduction of low attenuation plaque volume Reduction change in low attenuation plaque volume from baseline (start of the study) till the final visit will be measured using Coronary Computed Tomography Angiography (CCTA) 12 months
Secondary Reduction of total plaque volume, fibrous, lipid-rich and calcified plaque volumes using CCTA Reduction change of total plaque volume, fibrous, lipid-rich and calcified plaque volumes will be compared between baseline and at the end of the study. 12 months
Secondary Change in HgA1c lab values in the blood. Change in HgA1c lab values in the blood will be compared between baseline and at the end of the study. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Recruiting NCT06230406 - T-Mem GEne in Atherosclerosis
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Completed NCT02377310 - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography N/A
Not yet recruiting NCT01923012 - Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis Phase 2